Compare General Dynamics Corporation (GD) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs Recursion Pharmaceuticals Inc — how do they compare? General Dynamics Corporation trades at $392.19 (market cap $106.03B), while Recursion Pharmaceuticals Inc trades at $3.31 (market cap $1.81B). The key difference: General Dynamics Corporation is far larger — about 58.6× Recursion Pharmaceuticals Inc's market cap, and General Dynamics Corporation pays a 1.62% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| GD | RXRX | |
|---|---|---|
Market Cap | $106.03B | $1.81B |
Sector | Industrials | Health |
52-Week High | $395.97 | $6.79 |
52-Week Low | $312.53 | $2.84 |
Enterprise Value | $111.17B | $1.33B |
Dividend Yield | 1.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $395.97, up 1.0% on the day, near its 52-week high. The stock shows bullish technical momentum with consistent earnings beats, including Q2 2026 EPS of $4.24 versus $3.96 expected. Revenue growth is robust, with 2025 revenue at $52.55 billion, and the company secured a major $76.6 billion Navy contract in July 2026, boosting its backlog.
Outlook remains positive driven by defense budget tailwinds and strong contract wins, but valuation multiples like a P/E of 23.9 suggest limited upside from current levels. Risks include execution on large contracts and macroeconomic pressures on government spending.
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
